Eli Lilly and Company (LLY)
|Net Income (ttm)
|Feb 14, 2024
|764.47 - 784.00
|309.32 - 794.47
|Feb 6, 2024
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the... [Read more]
In 2023, LLY's revenue was $34.12 billion, an increase of 19.56% compared to the previous year's $28.54 billion. Earnings were $5.24 billion, a decrease of -16.08%.Financial Statements
According to 23 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price forecast is $671.82, which is a decrease of -14.18% from the latest price.
One of the most exciting things for an investor or trader is to look at tier account statement, or at the charts of what they own, and see a stock like Nvidia Corp. NASDAQ: NVDA or even the broader SP...
Eli Lilly and Novo Nordisk will remain leaders in the weight-loss drug market: Mizuho's Jared Holz
CNBC's Melissa Lee and Jared Holz, Mizuho Securities America healthcare sector strategist, join 'Squawk on Street' to discuss the weight-loss drug market, why he believes Eli Lilly and Novo Nordisk wi...
Eli Lilly 's CEO David Ricks told Reuters on Wednesday that the U.S. drugmaker expects to launch its obesity drug in Indian market as early as next year.
More transparency in pharmaceuticals will be a tailwind for the space, says BMO's Evan Seigerman
Evan Seigerman, BMO biotech analyst, joins 'Power Lunch' to discuss the health care ecosystems in pharmaceuticals.
Calls of the Day: Some bullish calls on Netflix, Eli Lilly, General Electric and Snowflake
The Investment Committee debates how to trade these names: Netflix, Eli Lilly, General Electric and Snowflake.
Eli Lilly could be the next stock to cross $1 trillion, says Jim Cramer
'Mad Money' host Jim Cramer looks at the current class of $1 trillion stocks and looks at what stocks could be poised to join the group.
Zealand's obesity drug shouldn't disrupt Novo Nordisk-Eli Lilly leadership: Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk obesity drugmakers after a new study out of Zealand Pharma analyzed the impact of GLP-1s on liver disease.
CNBC's Jim Cramer on Monday Eli Lilly, Berkshire Hathaway, Tesla and Broadcom have a chance to break the $1 trillion market cap barrier.
Zealand Pharma's Phase 2 trial was an "uniquivocal win" for a drug that can treat both liver disease and obesity, analysts said.
3-Stock Lunch: AMZN, WBA & LLY
Boris Schlossberg, BK Asset Management managing director of FX Strategy, joins 'Power Lunch' to discuss stock plays for three stocks including; Amazon.com, Walgreens and Eli Lilly.
INDIANAPOLIS , Feb. 20, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in Cowen's 44th Annual Health Care Conference on March 6, 2024. Anat Ashkenazi, executive vice president...
The European Union's healthcare regulator will this week review the use of Eli Lilly's approved Mounjaro drug against diabetes and obesity when prefilled in a multi-dose injection pen, according to a ...
Why Eli Lilly is a top pick to capitalize on GLP-1 drug craze
As the craze surrounding weight loss drugs like GLP-1s continues, many investors are wondering how to capitalize on the massive valuation given to this sector by many on Wall Street. Matt Higgins, RSE...
Calls of the Day: Trade Desk, Eli Lilly and Palo Alto Networks
The “Halftime Report” Investment Committee debate the biggest analyst calls of the day.
U.S.-based Eli Lilly and Denmark's Novo Nordisk have struck gold with their weight-loss drugs, sending their shares to stratospheric levels and putting them on par with some high-growth tech stocks.
Morgan Stanley analyst Terence Flynn increases his price target on shares of the drugmaker to $950 from $805.
Tiger Global has slashed its positions in four of the five Magnificent Seven tech stocks that account for almost half of its portfolio, while upping its stake in Amazon.com and piling into semiconduct...
Chart Master: Charting four 'unstoppable' stocks
Carter Worth, Worth Charting, joins 'Fast Money' to talk four stocks he says are 'unstoppable' right now: Eli Lilly, Nvidia, Abercrombie and Fitch and Deckers Outdoor.
Eli Lilly's Mounjaro drug is being launched in Britain this week, two pharmacy companies said on Wednesday, making the UK the fourth European country to introduce the highly-anticipated obesity drug.
Eli Lilly's weight-loss drug could be the best selling drug of all time, says Jim Cramer
'Mad Money' host Jim Cramer looks at the top performing stocks on the S&P 500 as it reached the 5,000 milestone.
Call of the Day: Eli Lilly getting a price target boost at Jefferies
Rob Sechan, CEO of NewEdge Wealth, joins CNBC's "Halftime Report" to to discuss the latest raise to Eli Lilly.
BioAge Labs, a biotech startup collaborating with Eli Lilly for trialing its obesity therapy, said on Tuesday it had raised $170 million in its latest funding round.
Hedge funds with long/short strategies have benefited in 2024 from a macroeconomic environment that has hit the most heavily shorted stocks particularly hard compared to their less shorted rivals, a n...
Lilly Pulitzer CEO talks cost pressures, innovation, new products areas including home and athletic
The most recent University of Michigan Consumer Sentiment Index reading showed a climb in consumer sentiment despite dealing with sticky inflation (prices have not adjusted as quickly to supply and de...
Novo Nordisk and Eli Lilly have given positive supply updates, aiming to reassure investors that they can continue to capitalize on the success of their drugs.